To the top

Page Manager: Webmaster
Last update: 9/11/2012 3:13 PM

Tell a friend about this page
Print version

Screening and evaluation … - University of Gothenburg, Sweden Till startsida
To content Read more about how we use cookies on

Screening and evaluation of anti-respiratory syncytial virus compounds in cultured cells.

Chapter in book
Authors Anna Lundin
Tomas Bergström
Edward Trybala
Published in Antiviral Methods and Protocols. Ed. Edwin Yunhao Gong. (Methods in molecular biology, 1030)
Volume 1030
Pages 345-63
ISBN 978-1-62703-483-8
ISSN 1940-6029
Publisher Humana Press
Publication year 2013
Published at Institute of Biomedicine, Department of Infectious Medicine
Pages 345-63
Language en
Keywords respiratory syncytial virus, antiviral drugs, screening, mode of action
Subject categories Clinical Medicine


Respiratory syncytial virus (RSV) is a highly contagious pathogen that infects mainly ciliated cells of respiratory epithelium and type 1 pneumocytes in the alveoli frequently causing serious respiratory disease in infants, elderly, and immunocompromised patients. At present, prevention/treatment of RSV infection is limited to the use of specific anti-RSV antibody or an aerosol formulation of ribavirin, a drug of suboptimal efficacy and low safety profile. There is an urgent need for development of novel anti-RSV drugs and virucides. Here we describe the cell culture-based methods used in our laboratory in identification of novel inhibitors of RSV including the P13 fusion inhibitor, and the PG545 virucide. Protocols for antiviral screening, evaluation of anti-RSV potency, and elucidation of mode of antiviral activity of test compounds are described.

Page Manager: Webmaster|Last update: 9/11/2012

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?